Our most recent research analysis, "Narcolepsy Market Forecast to 2027 - Global Analysis - by Type, Product, Distribution Channel, and Geography," projects that the global narcolepsy market will increase from US$ 2,026.8 million in 2018 to US$ 4,537.9 million in 2027, at a CAGR of 9.5%.

In 2018 North America accounted for the greatest portion of the global narcolepsy market, and this trend is anticipated to continue over the coming years. In North America, the US held the largest proportion. Five medications—Xyrem (sodium oxybate), Provigil (modafinil), Nuvigil (amodafonil), methylphenidate, and amphetamine—have been licenced for the treatment of narcolepsy. The US Food and Drug Administration has also given its approval to these medications. The most current approved medications in the US (solriamfetol) and European Union (pitolisant), which treat EDS associated with narcolepsy, are an H3R antagonist called pitolisant and a dopamine and norepinephrine reuptake inhibitor called pitolisant (pitolisant and solriamfetol).

Get Sample Copy of Report PDF: https://www.theinsightpartners.com/sample/TIPRE00003326/

The market trends and growth-promoting factors are highlighted in the report. Increased awareness of neurological disorders and rising prevalence of sleep-related neurological disorders are both factors contributing to the growth of the narcolepsy market. The expansion of the narcolepsy market, however, is likely to be hampered by the dangers and side effects of narcolepsy treatments.

Furthermore, throughout the projection period, market growth is anticipated to be supported by the expansion of the biopharmaceutical industry nationwide. The US economy is significantly impacted by this industry. The economic production of the biopharmaceutical sector was close to US$ 1.3 trillion in 2015, or 4% of all US output. This comprises US$ 659 billion in supplier and employee spending in addition to US$ 558 billion in revenue from biopharmaceutical enterprises. The US is the world's largest market for biopharmaceuticals and the leader in biopharmaceutical research and development, according to the International Trade Administration (ITA). Pharmaceutical businesses in the US do roughly half of all pharmaceutical R&D worldwide, accounting for US$75 billion, according to the Pharmaceutical Research and Manufacturers Association (PhRMA). and have been successful in creating new medications for which they own the intellectual property. For instance, in 2021, SK Biopharmaceuticals got permission for their narcolepsy medication Sunosi (solriamfetol), and its international business partner Jazz Pharmaceuticals introduced the medication in Canada. An FDA-approved medication called Sunosi is used to treat adults with narcolepsy or obstructive sleep apnea who experience excessive daytime sleepiness (EDS). Following the completion of Phase 1 clinical trials by the Korean drug developer, Jazz Pharmaceuticals received a licence to market the prescription medication. According to SK Biopharmaceuticals, approximately 15,000 Canadians are thought to have narcolepsy, while 6.4% of the country's citizens are thought to have sleep apnea. With more market launches, SK Biopharmaceuticals anticipates higher turnover, sales milestones, and royalties from the medicine. Major European nations including Germany, Denmark, France, and Italy all have access to the medicine. Sunosi is sold under licence by SK Biopharmaceuticals in 12 Asian nations, including South Korea, China, and Japan.

Market for Narcolepsy: Competitive Environment and Important Developments

·         Among the top businesses in the narcolepsy market are Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals plc, Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Mylan N.V., BIOPROJET, Shionogi & Co., Ltd., and Ligand Pharmaceuticals, Inc. With the creation of fresh, cutting-edge items by industry participants, the market share is projected to grow.

·         Jazz Pharmaceuticals plc's supplementary new drug application (sNDA) to change the labelling for Xyrem was approved by the FDA in October 2018.

·         Trintellix (vortioxetine), an oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, was made public by Takeda Pharmaceuticals USA, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Lundbeck in June 2016. It is now available in US pharmacies.

·         Shionogi Pharma Co., Ltd., which oversees manufacturing operations for the Shionogi group in Japan, built a new location in October 2018.

·         Takeda Pharmaceutical Company Limited purchased Shire plc in January 2019 to increase its geographic reach and take the lead in the US and Japan.

Browse More Related Reports by the insight partners:

Narcolepsy Drug Market

https://www.theinsightpartners.com/reports/narcolepsy-drug-market

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876